Instrument Inactif

Autres langues Argos Therapeutics Inc Nasdaq

Actions

US0402211033

Produits pharmaceutiques

Autres langues

24/09/19	Argos Therapeutics, Inc. Went Out of Business
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.
30/08/19	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.
21/03/19	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.
15/03/19	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.
13/02/19	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.
23/01/19	Motion for Asset Sale Approved for Argos Therapeutics, Inc.
22/01/19	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.
22/01/19	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.
22/01/19	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..
20/12/18	Bidding Procedure Approved for Argos Therapeutics, Inc.
06/12/18	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS
03/12/18	Argos Therapeutics, Inc. Announces Management Changes
30/11/18	Argos Therapeutics, Inc. Filed for Bankruptcy
30/11/18	Motion for Asset Sale Filed by Argos Therapeutics, Inc.
30/11/18	CELLSCRIPT, LLC and Cell Therapies, LLC entered into an asset purchase agreement to acquire Substantially All of the Non-Cash Assets of Argos Therapeutics, Inc. for approximately $1.7 million.
26/04/18	Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from S&P TMI Index
24/04/18	Argos Therapeutics, Inc. Announces Resignation of Sander van Deventer as Board of Directors
24/04/18	Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from NASDAQ Composite Index
20/04/18	Argos Therapeutics, Inc. announced that it has received $0.45 million in funding from Lummy (Hong Kong) Co., Ltd.
19/04/18	Argos Therapeutics, Inc. Reports Results of Interim Analysis of the Adapt Trial and Announces Review of Strategic Alternatives
19/04/18	Argos Therapeutics Announces Review of Strategic Alternatives
02/04/18	Argos Therapeutics, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
02/04/18	Argos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
06/01/18	Argos Therapeutics, Inc. announced that it expects to receive $1.5 million in funding from Lummy (Hong Kong) Co., Ltd.